lopinavir/ritonavir / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 77 Diseases   69 Trials   69 Trials   4434 News 


«12...2728293031323334353637...4546»
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Clinical, Review, Journal:  Medication and comedication in COVID-19 patients (Pubmed Central) -  Apr 30, 2020   
    Lopinavir/ritonavir is not effective. Supportive care is at present the mainstay of the treatment.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Clinical, Journal:  Association of Antiretroviral Drug Regimen With Viral Suppression in HIV-positive Children on Antiretroviral Therapy in Eswatini. (Pubmed Central) -  Apr 29, 2020   
    These findings highlight the critical importance of monitoring treatment regimen for optimizing treatment outcomes for pediatric HIV.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
  • ||||||||||  hydroxychloroquine / Generic mfg., azithromycin / Generic mfg., lopinavir/ritonavir / Generic mfg.
    New trial:  BACT-ovid: Bacteriotherapy in the Treatment of COVID-19 (clinicaltrials.gov) -  Apr 28, 2020   
    P,  N=70, Active, not recruiting, 
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Review, Journal:  Compounds with therapeutic potential against novel respiratory 2019 coronavirus. (Pubmed Central) -  Apr 26, 2020   
    The most promising compound is remdesivir (GS-5734), a nucleotide analog prodrug currently in clinical trials for treating Ebola virus infections...In addition, a combination of the human immunodeficiency virus type 1 (HIV-1) protease inhibitors lopinavir/ritonavir and interferon beta (LPV/RTV-IFN-β) was shown to be effective in patients infected with SARS-CoV...Therapeutics that target the coronavirus alone might not be able to reverse highly pathogenic infections. This minireview aimed to provide a summary of therapeutic compounds that showed potential in fighting SARS-CoV-2 infections.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Review, Journal:  ANTIVIRAL TREATMENT OF COVID-19. (Pubmed Central) -  Apr 26, 2020   
    Despite the urgent need to find an effective antiviral treatment for COVID-19 through randomized controlled studies, certain agents are being used all over the world based on either in-vitro or extrapolated evidence or observational studies. The most frequently used agents both in Turkey and all over the world including chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir and remdesivir will be reviewed here .Nitazoxanide and ivermectin were also included in this review as they have recently been reported to have an activity against SARS-CoV-2 in-vitro and are licensed for the treatment of some other human infections.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Clinical, Journal, Monotherapy:  HIV Viral Dynamics of Lopinavir/Ritonavir Monotherapy as Second-Line Treatment: A Prospective, Single-Arm Trial. (Pubmed Central) -  Apr 24, 2020   
    In this study, the rate of virologic failure among patients on a second-line lopinavir monotherapy regimen was relatively high and predicted by early detectable viremia. However, no LPV/r-associated resistance mutations were detected despite fluctuating low-level viremia, demonstrating the high genetic barrier to resistance of the protease inhibitor class which could be useful in RLS.
  • ||||||||||  Olumiant (baricitinib) / Incyte, Eli Lilly
    New P2/3 trial:  Baricitinib Therapy in COVID-19 (clinicaltrials.gov) -  Apr 23, 2020   
    P2/3,  N=12, Completed, 
  • ||||||||||  Olumiant (baricitinib) / Incyte, Eli Lilly
    Phase classification, Enrollment change, Trial completion date:  BARI-COVID: Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. (clinicaltrials.gov) -  Apr 21, 2020   
    P2/3,  N=200, Not yet recruiting, 
    However, no LPV/r-associated resistance mutations were detected despite fluctuating low-level viremia, demonstrating the high genetic barrier to resistance of the protease inhibitor class which could be useful in RLS. Phase classification: P3 --> P2/3 | N=60 --> 200 | Trial completion date: Apr 2020 --> Jul 2020
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Clinical, Review, Journal:  Emerging Therapeutic Strategies for COVID-19 patients. (Pubmed Central) -  Apr 21, 2020   
    Potential therapeutic strategies, including remdesivir, chloroquine phosphate, abidol, lopinavir/ritonavir, plasma, antibody, vaccine and stem cells are discussed in this review. With the number of patients increasing daily, there is an urgent need for effective therapeutic intervention.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Review, Journal:  Antiviral therapy in management of COVID-19: a systematic review on current evidence. (Pubmed Central) -  Apr 21, 2020   
    The results depicted that adding Lopinavir-Ritonavir to the standard treatment regimen of patients with severe COVID-19 has no benefits...The current evidence impede researchers from proposing an appropriate antiviral therapy against COVID-19, making the current situation a serious concern for international organizations such as World Health Organization (WHO). In the time of the current pandemic and future epidemics, organizations such as WHO should pursue more proactive actions and plan well-designed clinical trials so that their results can be used in managing future epidemics.
  • ||||||||||  Arbidol (umifenovir) / Pharmstandard
    Enrollment open, Trial completion date, Trial primary completion date:  Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus (clinicaltrials.gov) -  Apr 20, 2020   
    P3,  N=1000, Recruiting, 
    In the time of the current pandemic and future epidemics, organizations such as WHO should pursue more proactive actions and plan well-designed clinical trials so that their results can be used in managing future epidemics. Not yet recruiting --> Recruiting | Trial completion date: May 2020 --> Jan 2021 | Trial primary completion date: Apr 2020 --> Dec 2020
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Enrollment open:  CORIPREV-LR: COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir (clinicaltrials.gov) -  Apr 20, 2020   
    P3,  N=1220, Recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: May 2020 --> Jan 2021 | Trial primary completion date: Apr 2020 --> Dec 2020 Not yet recruiting --> Recruiting
  • ||||||||||  hydroxychloroquine / Generic mfg., azithromycin / Generic mfg., lopinavir/ritonavir / Generic mfg.
    New P2/3 trial:  Treatment for COVID-19 in High-Risk Adult Outpatients (clinicaltrials.gov) -  Apr 20, 2020   
    P2/3,  N=630, Recruiting, 
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Journal:  Lopinavir-ritonavir in severe COVID-19. (Pubmed Central) -  Apr 20, 2020   
    Enrolling by invitation --> Completed No abstract available
  • ||||||||||  VRC07-523LS / National Institute of Allergy and Infectious Diseases, IAVI, TaiMed Biologics, VRC01 / Acuitas Therap
    Trial completion date, Trial primary completion date:  Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission (clinicaltrials.gov) -  Apr 17, 2020   
    P1/2,  N=905, Recruiting, 
    No abstract available Trial completion date: Apr 2022 --> Dec 2031 | Trial primary completion date: Apr 2022 --> Jan 2028
  • ||||||||||  Arbidol (umifenovir) / Pharmstandard
    New P4 trial:  UAIIC: Umifenovir in Hospitalized COVID-19 Patients (clinicaltrials.gov) -  Apr 16, 2020   
    P4,  N=40, Enrolling by invitation, 
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Clinical, Journal:  Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. (Pubmed Central) -  Apr 16, 2020   
    Compared with the treatment of pneumonia-associated adjuvant drugs alone, the combination treatment with LPV/r and adjuvant drugs has a more evident therapeutic effect in lowering the body temperature and restoring normal physiological mechanisms with no evident toxic and side effects. In view of these conclusions, we suggested that the use of LPV/r combined with pneumonia-associated adjuvant drugs in the clinical treatment for patients with COVID-19 should be promoted.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Clinical, Journal:  COVID-19: A Brief Overview of the Discovery Clinical Trial. (Pubmed Central) -  Apr 16, 2020   
    The urgency of the situation favors a repurposing of active drugs but not only antivirals. This short communication focuses on four treatments recommended by WHO and included in the first clinical trial of the European Discovery project.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Review, Journal:  Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. (Pubmed Central) -  Apr 15, 2020   
    Antimicrobial stewardship programs, including infectious diseases pharmacists and physicians, are at the forefront of COVID-19 emergency preparedness. We encourage all readers to continue to assess clinical data as it emerges and share their experience within our community in a well-controlled, adequately powered fashion.
  • ||||||||||  interferon beta-1b / University of Hong Kong
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment (clinicaltrials.gov) -  Apr 14, 2020   
    P2,  N=127, Completed, 
    We encourage all readers to continue to assess clinical data as it emerges and share their experience within our community in a well-controlled, adequately powered fashion. Recruiting --> Completed | N=70 --> 127 | Trial completion date: Jul 2022 --> Mar 2020 | Trial primary completion date: Jan 2022 --> Mar 2020
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Journal:  Pursuing use of optimal formulations for paediatric HIV epidemic control - a look at the use of LPV/r oral pellets and oral granules. (Pubmed Central) -  Apr 14, 2020   
    Recruiting --> Completed | N=70 --> 127 | Trial completion date: Jul 2022 --> Mar 2020 | Trial primary completion date: Jan 2022 --> Mar 2020 Solutions to overcome these barriers include ensuring availability of an adequate supply of LPV/r oral pellets and oral granules, considering all programmatic and clinical factors when selecting paediatric ART formulations, and leveraging current resources to decrease paediatric HIV morbidity and mortality.
  • ||||||||||  levamisole / Generic mfg.
    Enrollment open:  Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19 (clinicaltrials.gov) -  Apr 12, 2020   
    P2/3,  N=30, Recruiting, 
    Overall, we suggest that the list of antiviral drugs identified by the MT-DTI model should be considered, when establishing effective treatment strategies for SARS-CoV-2. Not yet recruiting --> Recruiting